In this respect, endogenous Gal-9 has also been reported as driver of AML stem cells (Kikushige et al., 2015), and its inhibition is currently being tested in clinical trials [NCT05829226, NCT04666688]. Here, LGALS9 is linked to acute myeloid leukemia.